228 Characterization of miRNA expression pattern from in-vitro obtained exosomes of different urinary bladder cancer cell lines

2015 ◽  
Vol 14 (2) ◽  
pp. e228
Author(s):  
S. Baumgart ◽  
D. Jeppesen ◽  
J. Heinzelmann ◽  
M. Stöckle ◽  
M. Stampe Ostenfeld ◽  
...  
Tumor Biology ◽  
2014 ◽  
Vol 35 (5) ◽  
pp. 4599-4617 ◽  
Author(s):  
Rosário Pinto-Leite ◽  
Isabel Carreira ◽  
Joana Melo ◽  
Susana Isabel Ferreira ◽  
Ilda Ribeiro ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Regina Arantes-Rodrigues ◽  
Rosário Pinto-Leite ◽  
Lio Fidalgo-Gonçalves ◽  
Carlos Palmeira ◽  
Lúcio Santos ◽  
...  

The aim of this paper is to analyse sunitinib malatein vitroability to enhance cisplatin cytotoxicity in T24, 5637, and HT1376 human urinary bladder-cancer cell lines. Cells were treated with cisplatin (3, 6, 13, and 18 μM) and sunitinib malate (1, 2, 4, 6, and 20 μM), either in isolation or combined, over the course of 72 hours. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, acridine orange, and monodansylcadaverine staining and flow cytometry were performed. The combination index (CI) was calculated based on the Chou and Talalay method. In isolation, cisplatin and sunitinib malate statistically (). Autophagy and apoptosis studies showed a greater incidence when the combined treatment was put into use. This hints at the possibility of a new combined therapeutic approach. If confirmedin vivo, this conjugation may provide a means of new perspectives in muscle-invasive urinary bladder cancer treatment.


2014 ◽  
Vol 32 (1) ◽  
pp. 41.e11-41.e22 ◽  
Author(s):  
Rosário Pinto-Leite ◽  
Regina Arantes-Rodrigues ◽  
Rita Ferreira ◽  
Carlos Palmeira ◽  
Aura Colaço ◽  
...  

Author(s):  
Robert Nowakowski ◽  
Beniamin Grabarek ◽  
Anna Burnat-Olech ◽  
Dariusz Boroń ◽  
Monika Paul-Samojedny

Background: This study aimed to evaluate the variances in the expression pattern of mRNAs and miRNAs related to the EMT in the Ishikawa (histological grade 1; G1), EC-1A (histological grade 2; G2), and KLE (histological grade 3; G3) cell cultures under cisplatin treatment. Methods: Endometrial cancer cell lines were exposed to 75.22 mg (an average concentration of the drug used in patients with endometrial cancer) for 12.24 and 48 hours compared to the untreated cells (control). The molecular analysis included extraction of total RNA, microarray analysis (mRNA and miRNA), RTqPCR, and the ELISA assay. Results: Out of 226 mRNAs associated with the EMT, the number of mRNAs differentially expressed in endometrial cancer cell cultures treated with cisplatin compared to a control culture was as follows: Ishikawa line - 87 mRNAs; EC-1A - 84 mRNAs; KLE - 71 mRNAs (p<0.05). The greatest changes in the Ishikawa line treated with the drug compared to the control were noticed for mRNA STAT1 TGFβ1, SMAD3, FOXO8, whereas in EC-1A, they were mRNA TGFβ1, BAMBI, SMAD4, and in KLE mRNA COL1A1, FOXO8, TGFβ1. The analysis also showed that miR-106a, miR-30d, miR-300 are common for all cell lines used in this experiment. Conclusion: Cisplatin changes the expression profile of genes associated with EMT in endometrial cancer cell lines. It seems that the expression pattern of TGFβ1 might be a promising, supplementary molecular marker of the effectiveness of cisplatin therapy. The analysis showed that miR-30d, miR-300, and miR-106a are involved in the regulation of the expression of EMT-related genes.


Sign in / Sign up

Export Citation Format

Share Document